Opioid Agonist Therapy
A new guideline recommends opioid agonist therapy with buprenorphine-naloxone as first-line for the treatment of opioid use disorder.
Slow-Release Oral Morphine, a Promising Opioid Agonist Therapy Alternative to Buprenorphine, MethadoneJanuary 11, 2018
Slow-release oral morphine may be a valuable tool to help reduce the number of deaths from opioid-related overdose.
Immediate access to opioid agonist treatment for patients presenting with opioid use disorder may provide greater health benefits at less cost than observed standard of care.
A small fraction of prescriptions for Medicare patients are for opioid agonist therapy, despite higher rates of abuse.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Predicting the Magnitude of Placebo Analgesia in Chronic Pain
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Examining the Efficacy of Different Oxygen Flow Rates for Cluster Headache Attacks
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- Nonsinogenic Headache vs Chronic Rhinosinusitis Differential Diagnosis Based on SNOT-22 Patterns
- Patterns of Non-Medical Prescription Opioid Use in Adolescents
- Factors Promoting Participation in Self-Management Training Program for Chronic Pain
- Majority of Internists Still Have Financial Ties to Industry
- Advantages and Challenges of Community-Based Health Interventions Examined